Edwards Lifesciences TAVR cuts risk of death or heart failure events by 33% in moderate aortic stenosis trial

• Edwards Lifesciences’ PROGRESS trial found transcatheter aortic valve replacement superior to clinical surveillance in moderate aortic stenosis patients with at-risk features.
• Treatment reduced the combined risk of death or heart failure events over two years; mortality alone was similar between groups.
• Patients receiving treatment had fewer heart failure hospitalizations and improved quality of life, with no deaths or disabling strokes at 30 days.
• Results were presented at Transcatheter Cardiovascular Therapeutics 2026 and simultaneously published in The New England Journal of Medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611021240BIZWIRE_USPR_____20261102_BW440960) on November 02, 2026, and is solely responsible for the information contained therein.